首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 6期丙型肝炎 => 病毒性肝炎 =>3D方案(帕里瑞韦/利托那韦/奥比他韦联..
3D方案(帕里瑞韦/利托那韦/奥比他韦联合达塞布韦)治疗初治基因1b型慢性丙型肝炎患者的效果分析
Clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1b chronic hepatitis C
文章发布日期:2017年05月04日  来源:  作者:王博文,康文,孙永涛,等  点击次数:154次  下载次数:12次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:目的观察3D方案(帕里瑞韦/利托那韦/奥比他韦联合达塞布韦)治疗初治基因1b型慢性丙型肝炎患者的临床疗效。方法纳入2015年9月-2016年4月就诊于第四军医大学唐都医院传染科初治的基因1b型慢性丙型肝炎患者10例。给予3D方案治疗12周,治疗结束后随访24周,观察治疗结束后12周和24周持续病毒学应答(SVR12和SVR24)情况,并监测生化学变化和不良反应发生情况。计量资料多组间比较采用方差分析。结果治疗2周,70%患者HCV RNA达到检测下限以下;治疗12周,100%患者HCV RNA检测不到,生化学应答率达100%。SVR12和SVR24均为100%。治疗期间和随访24周患者ALT、AST和炎症性指标干扰素诱导蛋白10均较治疗前显著下降(F值分别为20.15、10.83、13.67,P值均<0.05)。主要不良反应包括乏力和头痛,无严重不良事件。结论对于初治的基因1b型慢性HCV感染者,经3D方案治疗可获得极高的SVR率以及生化学应答率,并可改善患者肝功能,且具有良好的安全性。
【Abstract】:ObjectiveTo investigate the clinical effect of 3D regimen (paritaprevir/ritonavir/ombitasvir combined with dasabuvir) in treatment-naive patients with genotype 1b chronic hepatitis C. MethodsA total of 10 patients with genotype 1b chronic hepatitis C who were treated for the first time in Department of Infectious Diseases in our hospital from September 2015 to April 2016 were enrolled. All patients were treated with 3D regimen for 12 weeks and followed up for 24 weeks after treatment. Sustained virologic response at 12 and 24 weeks (SVR12 and SVR24) was observed, and the changes in biochemical parameters and the incidence of adverse events were monitored. An analysis of variance was used for comparison of continuous data between groups. ResultsAfter 2 weeks of treatment, 70% of all patients achieved an HCV RNA level reduced to below the detection level, and after 12 weeks of treatment, HCV RNA was not detected in any patient, resulting in a biochemical response rate of 100%. Both SVR12 and SVR24 were 100%. There were significant reductions in the levels of alanine aminotransferase, aspartate aminotransferase, and the inflammatory marker interferon-inducible protein 10 after treatment (F=20.15, 10.83, and 13.67, all P<0.05). The most common adverse events were weakness and headache and no serious adverse events were observed. ConclusionIn treatment-naive patients with genotype 1b chronic hepatitis C, 3D regimen achieves high SVR rate and biochemical response rate, improves patients′ liver function, and has good safety.
【关键字】:肝炎, 丙型, 慢性; 抗病毒药; 治疗
【Key words】:hepatitis C, chronic; antiviral agents; therapy
【引证本文】:王博文, 康文, 孙永涛, 等. 3D方案(帕里瑞韦/利托那韦/奥比他韦联合达塞布韦)治疗初治基因1b型慢性丙型肝炎患者的效果分析[J]. 临床肝胆病杂志, 2017, 33(6): 1092-1095.

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号